Brief: Sun Pharma Says Philogen Resubmits Marketing Authorization Application To EMA For Nidlegy In Melanoma
BRIEF-Sun Pharma Says Philogen Resubmits Marketing Authorization Application To EMA For Nidlegy In Melanoma July 27 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS:
SUN PHARMA - PHILOGEN RESUBMITS MARKETING AUTHORIZATION APPLICATION TO EMA FOR NIDLEGY IN MELANOMA
SUN PHARMA - NIDLEGY MARKETING AUTHORIZATION APPLICATION RESUBMITTED TO EMA
Source text: ID:nBSE7mx7cX
Further company coverage: SUN.NS
((reuters.briefs@thomsonreuters.com;))
Recent news on Sun Pharmaceutical Industries
See all newsROI-US blue wave reshapes Asia's winners and losers: Manishi Raychaudhuri
Brief: Sun Pharma Clarifies Regarding News Report Relating To Company's Assam Facility
Street View: India's Sun Pharma Organon buy, psoriasis drug are risk factors
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses